Meeting
2021 Genitourinary Cancers Symposium
Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).
Authors
Nathaniel Wilson
University of Texas Health Science Center at Houston, Houston, TX
Nathaniel Wilson , Andrew James Wiele , Devaki Shilpa Surasi , Priya Rao , Kanishka Sircar , Amishi Yogesh Shah , Giannicola Genovese , Jose A. Karam , Christopher G. Wood , Nizar M. Tannir , Pavlos Msaouel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 324)
DOI
10.1200/JCO.2021.39.6_suppl.324
Abstract #
324
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
First Author: Philippe Barthelemy
Poster
2023 ASCO Annual Meeting
Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.
First Author: Nadezhda Omelchenko
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu